Perioperative toripalimab improves event-free survival in non-small cell lung cancer

1. In patients with resectable stage III non-small cell lung cancer, perioperative toripalimab plus chemotherapy increased rates of tumor and lymph node downstaging and improved event-free survival compared to chemotherapy alone. 2. Operative approach, complete resection, hospital stay, and perioperative complication rates remained comparable between study groups. Evidence Rating Level: 1…